Feedback
EGFR T790M Mutation Detection in Circulating Tumor DNA by Digital Droplet PCR
2012868
Ordering Recommendation

Monitor for development of EGFR T790M drug-resistant mutation in patients administered tyrosine kinase inhibitor (TKI) therapy for EGFR-mutant non-small cell lung cancer. Monitor response to therapy and disease progression in patients treated with EGFR T790M-specific TKIs.

Mnemonic
EGFR T790M
Methodology
Polymerase Chain Reaction
Performed
Varies
Reported
10-12 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Whole blood in two 10 mL Cell-Free DNA (cfDNA) BCT Tubes (ARUP Supply #52358) available online through eSupply or contacting ARUP Client Services at (800) 522-2787. Also acceptable: CSF collected in a sterile container. 
Specimen Preparation
Whole Blood: Transport 20 mL whole blood. (Min: 16 mL)
CSF: Transport 4 mL CSF. (Min: 4 mL) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
FFPE tissue. Whole Blood collected in non-cfDNA BCT tubes. 
Remarks
 
Stability
Whole Blood: Ambient: 5 days; Refrigerated: 5 days; Frozen: Unacceptable
CSF: Ambient: Unacceptable; Refrigerated: 5 days; Frozen: Unacceptable 
Reference Interval
Interpretive Data
Refer to report.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Components
Component Test Code*Component Chart NameLOINC
2012869EGFR T790M Result55769-4
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases